HRP20020593B1 - Liječenje ozljeda mozga, kralježnične moždine i živca - Google Patents

Liječenje ozljeda mozga, kralježnične moždine i živca

Info

Publication number
HRP20020593B1
HRP20020593B1 HR20020593A HRP20020593A HRP20020593B1 HR P20020593 B1 HRP20020593 B1 HR P20020593B1 HR 20020593 A HR20020593 A HR 20020593A HR P20020593 A HRP20020593 A HR P20020593A HR P20020593 B1 HRP20020593 B1 HR P20020593B1
Authority
HR
Croatia
Prior art keywords
nerval
speech
brain
injury
treatment
Prior art date
Application number
HR20020593A
Other languages
English (en)
Croatian (hr)
Inventor
Vink Robert
John Nimmo Alan
Original Assignee
F. Hoffmann - La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann - La Roche Ag filed Critical F. Hoffmann - La Roche Ag
Publication of HRP20020593A2 publication Critical patent/HRP20020593A2/xx
Publication of HRP20020593B1 publication Critical patent/HRP20020593B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HR20020593A 2000-01-18 2001-01-18 Liječenje ozljeda mozga, kralježnične moždine i živca HRP20020593B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ5146A AUPQ514600A0 (en) 2000-01-18 2000-01-18 Brain injury treatment
PCT/AU2001/000046 WO2001052844A1 (en) 2000-01-18 2001-01-18 Brain, spinal and nerve injury treatment

Publications (2)

Publication Number Publication Date
HRP20020593A2 HRP20020593A2 (en) 2005-10-31
HRP20020593B1 true HRP20020593B1 (hr) 2011-03-31

Family

ID=3819274

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20020593A HRP20020593B1 (hr) 2000-01-18 2001-01-18 Liječenje ozljeda mozga, kralježnične moždine i živca

Country Status (20)

Country Link
US (5) US6841551B2 (enExample)
EP (1) EP1261335B1 (enExample)
JP (1) JP4794794B2 (enExample)
KR (1) KR100780119B1 (enExample)
CN (1) CN1261095C (enExample)
AU (2) AUPQ514600A0 (enExample)
BR (1) BR0107695A (enExample)
CA (1) CA2397723C (enExample)
CZ (1) CZ20022804A3 (enExample)
DE (1) DE60139244D1 (enExample)
HR (1) HRP20020593B1 (enExample)
HU (1) HUP0301920A3 (enExample)
IL (2) IL150548A0 (enExample)
MX (1) MXPA02007004A (enExample)
NO (1) NO329320B1 (enExample)
NZ (2) NZ534278A (enExample)
RU (1) RU2276996C2 (enExample)
WO (1) WO2001052844A1 (enExample)
YU (1) YU54702A (enExample)
ZA (1) ZA200205715B (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
BRPI0407071B8 (pt) 2003-01-28 2021-05-25 Ironwood Pharmaceuticals Inc peptídeo purificado, seu método de produção e composição farmacêutica para o tratamento de distúrbios gastrointestinais
GB0410215D0 (en) * 2004-05-07 2004-06-09 Lescroart Pol Nerve damage
US20060069086A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
JP2008531509A (ja) 2005-02-25 2008-08-14 エフ．ホフマン−ラ ロシュ アーゲー 医薬品成分の改良された分散性を有する錠剤
WO2006110118A1 (fr) * 2005-04-15 2006-10-19 Victor Pavlovich Kutnyak Produit cytoprotecteur
WO2006116634A2 (en) 2005-04-26 2006-11-02 Novadaq Technologies, Inc. Method and apparatus for vasculature visualization with applications in neurosurgery and neurology
US20060239921A1 (en) 2005-04-26 2006-10-26 Novadaq Technologies Inc. Real time vascular imaging during solid organ transplant
WO2007016790A1 (en) * 2005-08-10 2007-02-15 Novadaq Technologies, Inc. Intra-operative head & neck nerve mapping
US20070122344A1 (en) * 2005-09-02 2007-05-31 University Of Rochester Medical Center Office Of Technology Transfer Intraoperative determination of nerve location
US20070154448A1 (en) * 2005-11-22 2007-07-05 Ted Reid Methods and compositions using Substance P to promote wound healing
US8945623B2 (en) * 2006-05-03 2015-02-03 Warsaw Orthopedic, Inc. Compositions comprising biomembrane sealing agent for treatment of neuronal injury, and methods of use
US20080161744A1 (en) * 2006-09-07 2008-07-03 University Of Rochester Medical Center Pre-And Intra-Operative Localization of Penile Sentinel Nodes
US20080241121A1 (en) * 2007-04-02 2008-10-02 Daniela Salvemini Inhibitors of the ceramide metabolic pathway as adjuncts to opiates for pain
US20100086543A1 (en) * 2007-04-02 2010-04-08 Saint Louis University Compositions and methods for treating conditions associated with ceramide biosynthesis
DK2170930T3 (da) 2007-06-04 2012-11-05 Synergy Pharmaceuticals Inc Agonister af guanylatcyclase, anvendelige til behandlingen af gastrointestinale sygdomme, inflammation, cancer og andre sygdomme
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
KR20100055430A (ko) * 2007-07-19 2010-05-26 애들레이드 리서치 앤드 이노베이션 피티와이 리미티드 두개내압 감소 방법
US8406860B2 (en) 2008-01-25 2013-03-26 Novadaq Technologies Inc. Method for evaluating blush in myocardial tissue
US10219742B2 (en) 2008-04-14 2019-03-05 Novadaq Technologies ULC Locating and analyzing perforator flaps for plastic and reconstructive surgery
US20090263507A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Biological markers and response to treatment for pain, inflammation, neuronal or vascular injury and methods of use
WO2009135178A2 (en) 2008-05-02 2009-11-05 Flower Robert W Methods for production and use of substance-loaded erythrocytes (s-les) for observation and treatment of microvascular hemodynamics
EP2328910B1 (en) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
ES2657938T3 (es) 2008-12-31 2018-03-07 Ardelyx, Inc. Compuestos y métodos para inhibir el antipuerto mediado por NHE en el tratamiento de trastornos asociados a la retención de líquidos o a la sobrecarga de sales y trastornos del tracto gastrointestinal
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US8852566B2 (en) * 2009-03-26 2014-10-07 Warsaw Orthopedic, Inc. Compositions and methods for preferential distribution of active agents to injury sites
US10492671B2 (en) 2009-05-08 2019-12-03 Novadaq Technologies ULC Near infra red fluorescence imaging for visualization of blood vessels during endoscopic harvest
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
JP6154135B2 (ja) * 2010-12-03 2017-06-28 国立大学法人 岡山大学 外傷性神経障害治療剤
WO2012125020A1 (en) * 2011-03-14 2012-09-20 N.V. Nutricia Method for treating neurotrauma
JP6028096B2 (ja) 2012-06-21 2016-11-16 ノバダック テクノロジーズ インコーポレイテッド 血管造影及びかん流の定量化並びに解析手法
EP2887964B1 (en) 2012-08-21 2019-07-03 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014169094A2 (en) 2013-04-12 2014-10-16 Ardelyx, Inc Nhe3-binding compounds and methods for inhibiting phosphate transport
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
BR112015032534B1 (pt) * 2013-07-02 2020-03-03 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Uso de compostos ou sal ou solvato farmaceuticamente aceitável dos mesmos
BR112015032161A2 (pt) * 2013-07-02 2017-07-25 Eustralis Pharmaceuticals Ltd Trading As Pressura Neuro método para prevenir e/ou tratar encefalopatia traumática crônica, composição farmacêutica e uso de antagonista do receptor da substância p
EP3016658A4 (en) * 2013-07-02 2017-03-15 Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) Method for preventing and/or treating chronic traumatic encephalopathy-iv
EP3016659A4 (en) * 2013-07-02 2017-03-15 Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) Method for preventing and/or treating chronic traumatic encephalopathy-iii
WO2016049756A1 (en) 2014-09-29 2016-04-07 Novadaq Technologies Inc. Imaging a target fluorophore in a biological material in the presence of autofluorescence
JP6487544B2 (ja) 2014-10-09 2019-03-20 ノバダック テクノロジーズ ユーエルシー 蛍光媒介光電式容積脈波記録法を用いた組織中の絶対血流の定量化
WO2018129557A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Inhibitors of nhe-mediated antiport
KR20240090875A (ko) 2017-01-09 2024-06-21 알데릭스, 인코포레이티드 위장관 장애를 치료하는 데 유용한 화합물
US11140305B2 (en) 2017-02-10 2021-10-05 Stryker European Operations Limited Open-field handheld fluorescence imaging systems and methods
CA3149980A1 (en) * 2019-08-23 2021-03-04 Pierre Vankan Therapeutic methods and uses thereof
WO2021202286A1 (en) * 2020-03-30 2021-10-07 Dignify Therapeutics, Llc Compositions and methods for treating autonomic dysreflexia

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0721778A2 (en) * 1994-12-12 1996-07-17 Pfizer Inc. NK-1 receptor antagonists for the treatment of neuronal injury and stroke
US5610165A (en) * 1994-02-17 1997-03-11 Merck & Co., Inc. N-acylpiperidine tachykinin antagonists
US5716979A (en) * 1992-08-13 1998-02-10 Warner-Lambert Company Tachykinin antagonists
WO1999064009A1 (en) * 1998-06-11 1999-12-16 Merck Sharp & Dohme Limited Use of an nk-1 receptor antagonist for treating cognitive disorders

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4481139A (en) * 1983-04-13 1984-11-06 Board Of Regents, The University Of Texas System Peptide antagonists of substance P
US4985896A (en) * 1985-03-29 1991-01-15 Canon Kabushiki Kaisha Laser driving device
GB8929070D0 (en) * 1989-12-22 1990-02-28 Fujisawa Pharmaceutical Co Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same
US4981744A (en) * 1990-04-24 1991-01-01 Swank Michael W Non-planar expandable honeycomb structure
US5744482A (en) * 1994-10-05 1998-04-28 Eli Lilly And Company Serotonin agonist in combination with a tachykinin receptor antagonist in the treatment or prevention of migraine
US5998444A (en) * 1995-10-24 1999-12-07 Zeneca Ltd. Piperidinyl compounds as NK1 or NK2 antagonists
AU4918796A (en) * 1995-02-10 1996-08-27 Eli Lilly And Company Methods of treating or preventing psychiatric disorders
US5795894A (en) * 1995-05-02 1998-08-18 Schering Corporation Piperazino derivatives as neurokinn antagonists
US5990125A (en) 1996-01-19 1999-11-23 Pfizer Inc. NK-1 receptor antagonists for the treatment of cancer
AU5265596A (en) * 1996-04-12 1997-11-07 Neotech Medical Innovations, Inc. Composition and method for the treatment of premenstrual syndrome
US5977104A (en) * 1996-12-02 1999-11-02 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating bipolar disorders
JP2001513562A (ja) * 1997-08-28 2001-09-04 メルク エンド カムパニー インコーポレーテッド 月経前または黄体後期症候群の治療方法
PT1035115E (pt) 1999-02-24 2005-01-31 Hoffmann La Roche Derivados de 4-fenilpiridina e a sua utilizacao como antagonistas do receptor nk-1
CN1131212C (zh) 1999-02-24 2003-12-17 弗·哈夫曼-拉罗切有限公司 苯基－和吡啶基衍生物
PL350428A1 (en) 1999-02-24 2002-12-16 Hoffmann La Roche 3-phenylpyridine derivatives and their use as nk-1 receptor antagonists
US6291465B1 (en) 1999-03-09 2001-09-18 Hoffmann-La Roche Inc. Biphenyl derivatives
US6274588B1 (en) 1999-05-31 2001-08-14 Hoffmann-La Roche Inc. 4-phenyl-pyrimidine derivatives
JO2308B1 (en) 1999-05-31 2005-09-12 اف. هوفمان- لاروش أيه جي‏ Derivatives of phenylpyrmidine
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
US6479433B1 (en) * 2000-10-02 2002-11-12 Smithers-Oasis Company Polyurethane foam composites for grower applications and related methods

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716979A (en) * 1992-08-13 1998-02-10 Warner-Lambert Company Tachykinin antagonists
US5610165A (en) * 1994-02-17 1997-03-11 Merck & Co., Inc. N-acylpiperidine tachykinin antagonists
EP0721778A2 (en) * 1994-12-12 1996-07-17 Pfizer Inc. NK-1 receptor antagonists for the treatment of neuronal injury and stroke
WO1999064009A1 (en) * 1998-06-11 1999-12-16 Merck Sharp & Dohme Limited Use of an nk-1 receptor antagonist for treating cognitive disorders

Also Published As

Publication number Publication date
US10201568B2 (en) 2019-02-12
EP1261335A1 (en) 2002-12-04
JP4794794B2 (ja) 2011-10-19
HK1054872A1 (en) 2003-12-19
HUP0301920A3 (en) 2010-03-29
NZ519990A (en) 2004-10-29
RU2276996C2 (ru) 2006-05-27
HRP20020593A2 (en) 2005-10-31
EP1261335B1 (en) 2009-07-15
BR0107695A (pt) 2002-10-15
US6841551B2 (en) 2005-01-11
US20050107380A1 (en) 2005-05-19
CZ20022804A3 (cs) 2002-11-13
DE60139244D1 (de) 2009-08-27
MXPA02007004A (es) 2004-10-15
NO20023423L (no) 2002-09-16
KR100780119B1 (ko) 2007-11-27
HUP0301920A2 (hu) 2003-09-29
US20160030474A1 (en) 2016-02-04
AU782799B2 (en) 2005-09-01
IL150548A (en) 2011-05-31
CN1261095C (zh) 2006-06-28
KR20020075784A (ko) 2002-10-05
NO20023423D0 (no) 2002-07-17
JP2003520232A (ja) 2003-07-02
NZ534278A (en) 2005-08-26
WO2001052844A1 (en) 2001-07-26
EP1261335A4 (en) 2004-09-22
US20030109417A1 (en) 2003-06-12
AU2656001A (en) 2001-07-31
YU54702A (sh) 2006-01-16
US9186404B2 (en) 2015-11-17
ZA200205715B (en) 2003-10-17
IL150548A0 (en) 2003-02-12
US20180071333A1 (en) 2018-03-15
RU2002121640A (ru) 2004-03-27
US20090253698A1 (en) 2009-10-08
CA2397723A1 (en) 2001-07-26
CN1426302A (zh) 2003-06-25
CA2397723C (en) 2010-08-31
NO329320B1 (no) 2010-09-27
AUPQ514600A0 (en) 2000-02-10
PL358251A1 (en) 2004-08-09

Similar Documents

Publication Publication Date Title
HRP20020593B1 (hr) Liječenje ozljeda mozga, kralježnične moždine i živca
CY1107054T1 (el) Ενωσεις διτοσυλικου αλατος κιναζολινης
PT1446387E (pt) Derivados de aril-1,4-pirazina substituídos
MY130489A (en) Substituted aryl 1, 4-pyrazine derivatives
ATE350044T1 (de) Thrombopoietinmimetika
IL144643A0 (en) Jak-3 inhibitors for treating allergic disorders
DE60124684D1 (de) Sulfonamido-substituierte verbrückte bicycloalkylderivative
MY136707A (en) Thrombopoietin mimetics
DE60020613D1 (de) (S,S)-Reboxetin zur Behandlung von Fibromyalgie und anderen somatoformen Störungen
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
ATE355278T1 (de) Isochinolinon derivate als parp inhibitoren
GB0025173D0 (en) Therapeutic agents
DE60025632D1 (de) Thrombopoietin-mimetika
AU2002361811A8 (en) 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
NO20035025D0 (no) Anvendelse av osteopontin for behandling og/eller for å hindre nevrologiskesykdommer
MX238203B (es) Tratamiento de semillas con combinaciones de piretrinas, piretroides y tlametoxam.
ATE422498T1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
DK1463735T3 (da) Imidazo-2,1-B -1,3,4-thiadiazol-sulfonamider
MXPA03003741A (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
IL161501A0 (en) Methods of preventing and treating flavivirus infection in animals
ATE383874T1 (de) Perylenequinonen zur anwendung als sonosensitizer
YU89103A (sh) Novi postupak lečenja opsesivno-kompulsivnog poremećaja (okp) i poremećaja povezanih sa okp-om, korišćenjem gvg-a
TR200200278T2 (tr) Kalsilitik bileşimler
DE69514928D1 (de) Gegen protozoen wirksamezyklische tetrapeptide
DE60109594D1 (de) R-eliprodil zur behandlung von glaucoma

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20110314

Year of fee payment: 11

B1PR Patent granted
PBON Lapse due to non-payment of renewal fee

Effective date: 20120119